Multi-drug resistant tuberculosis: An iatrogenic problem

BioScience Trends

Volumn 4, Issue 2, 2010, Pages 48-55

  Kant, Surya ^a   Maurya, Anand K ^a   Kushwaha, R A S ^a   Nag, Vijaya L ^b   Prasad, Rajendra ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti tuberculosis drug; DOTS; Multi drug resistant TB (MDR TB); Tuberculosis (TB)

Indexed keywords

ANTIBIOTIC RESISTANCE; DIRECTLY OBSERVED THERAPY; HUMAN; IATROGENIC DISEASE; METHODOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PHYSIOLOGY; REVIEW;

DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; IATROGENIC DISEASE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77956902890     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. WHO. The World Health Report 2004: Changing History. World Health Organization, Geneva, Switzerland, 2004.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999; 282:677-686.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163:1009-1021.
4. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. World Health Organization, Geneva, Switzerland, 2006; p. 242
5. Singla R. Management of drug resistance pulmonary Tuberculosis in India. The Cardiothoracic Journal. 1995; 1:312-316.
6. Guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2006. 361
7. Francis J. Curry National Tuberculosis Center and California Department of Health Services, 2004: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians.
8. Paramasivan CN, Bhaskaran K, Venkataraman P, Chandrasekaran V, Narayanan PR. Surveillance of drug resistance in tuberculosis in the state of Tamil Nadu. Ind J Tub. 2000; 47:27-33.
9. Trivedi SS, Desai SG. Primary TB drug resistance and acquired Rifampicin resistance in Gujarat, India. Tubercle. 1988; 69:37-42.
10. Jain NK, Chopra KK, Prasad G. Initial and acquired Isoniazid and Rifampicin resistance to M. tuberculosis and its implications for treatment. Indian J Tuberc. 1992; 39:121-124.
11. Datta M, Radhamani MP, Salvaraj R, Paramsivan CN, Gopalana BN, Sudeendraa CR, Prabhakar R. Critical assessment of smear positive pulmonary TB patients after chemotherapy under the district TB programme. Tuber Lung Dis. 1993; 74:180-186.
12. Costello HD, Caras GJ, Snider DE Jr. Drug resistance among previously treated tuberculosis patients, a brief report. Tubercle. 1980; 121:313-316.
13. Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem. 1996; 65:215-239.
14. David HL. Basis for lack of drug susceptibility of atypical Mycobacteria. Rev Infect Dis. 1981; 3:878-884.
15. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998; 393:537-544.
16. Telenti A. Genetics of drug resistant tuberculosis. Thorax. 1998; 53:793-797.
17. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998; 79:3-29.
18. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium Tuberculosis. In: Molecular genetics of Mycobacteria (Hatfull GF, Jr. Jacobs WR, eds.). Washington American Society for Microbiology, 2000. (in press)
19. Veen J. Drug Resistant tuberculosis: back to sanatoria, surgery and cod-liver oil? Eur Respir J. 1995; 8:1073-1075.
20. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006; 55:301-305.
21. Centers for Disease Control and Prevention (CDC). Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 2006; 55:11-76.
22. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006; 194:479-485.
23. Blower SM, Chou T. Modeling the emergence of the "hot zones": tubercu losis and the amplification dynamics of drug resistance. Nat Med. 2004; 10:1111-1116.
24. Guidelines for surveillance of drug resistance in tuberculosis. Geneva, World Health Organization, 2003 (WHO/CDS/TB/2003.320; WHO/CDS/CSR/ RMD/2003.3).
25. Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD global project on antituberculosis drug resistance surveillance, 1999-2002. Geneva, World Health Organization, 2004 (WHO/HTM/ TB/2004.343).
26. Global tuberculosis control: surveillance, planning, financing. WHO report 2004. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.331).
27. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis. 2002; 6:858-864.
28. Holdiness MR. Cerebrospinal fl uid pharmacokinetics of the antitubercu losis drugs. Clin Pharmacokinet. 1985; 10:532-524.
29. Daley CL. Mycobacterium tuberculosis complex. In: Antimicrobial therapy and vaccines (Yu VL, Merigan TC Jr, Barriere SL, eds.). Philadelphia, Lippincott Williams & Wilkins, 1999; 8:531-536.
30. Joshi PL. HIV/AIDS in India. Ranbaxy Science Foundation Round Table Conference Series. 2000; 6:27-32.
31. Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res. 2004; 120:377-386.
32. TB/HIV: a clinical manual. Geneva, WHO, 2003 (WHO/ HTM/TB/2004.329).
33. Telenti A, Iseman M. Drug-resistant tuberculosis: what do we do now? Drugs. 2000; 59:171-179.
34. Dickinson JM, Allen BW, Mitchison DA. Slide culture sensitivity tests. Tubercle. 1989; 70:115-121.
35. Jacobs WR Jr, Barletta RG, Udani R, Chan J, Kalkut G, Sosne G, Kieser T, Sarkis GJ, Hatfull GF, Bloom BR. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science. 1993; 260:819-822.
36. Cooksey RC, Crawford JT, Jacobs WR Jr, Shinnick TM. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother. 1993; 37:1348-1352.
37. Good RC, Mastro TD. The modern mycobacteriology laboratory. How it can help the clinician. Clin Chest Med. 1989; 10:315-322.
38. Huebner RE, Good RC, Tokars JI. Current practices in mycobacteriology: results of a survey of state public health laboratories. J Clin Microbiol. 1993; 31:771-775.
39. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341:647-650.
40. Samaria JK, Matah SC, et al. Multidrug Resistant T.B. Postgraduate update, A. Passi Publication.
41. Treatment of tuberculosis: Guidelines for National Programmes. Geneva, WHO, 2003(WHO CDS/ TB/2003.313).
42. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. Geneva, WHO, 1997 (Document WHO /TB/96:210).
43. Mukerjee JS, Rich ML, Socci AR. Programmes and principles in treatment of multidrug resistant tuberculosis. Lancet. 2004; 363:474-81.
44. Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Effi cacy and safety of kanamycin, ethionamide, PAS and cycloserin in multidrug resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci. 2006; 48:183-186.
45. Iseman MD. Treatment of multidrug resistant tuberculosis. New Eng J Med. 1993; 329:784-791.
46. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug resistant mycobacterium tuberculosis. Am Rev Respir Dis. 1990; 141:623-625.
47. Takeda S, Maeda H, Hayakawa M, Sawabata N, Maekura R. Current surgical intervention for multidrug resistant tuberculosis. Ann Thorac Surg. 2005; 79:959-963.
48. DOTS-Plus Guidelines. Revised National Tuberculosis Control Programme March 2006.
49. Prasad R. Management of multi-drug resistant tuberculosis: Practitioner's view point. Indian J Tuberc. 2007; 54:3-11..
50. Arora VK, Arora Raksha (1st. ed.). Practical Approach to Tuberculosis Management. Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, India, 2006.